278 related articles for article (PubMed ID: 30101616)
1. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
2. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
3. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
Chiuzan C; Dehbi HM
Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
[TBL] [Abstract][Full Text] [Related]
4. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
5. On the relative efficiency of model-assisted designs: a conditional approach.
Lin R; Yuan Y
J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
[TBL] [Abstract][Full Text] [Related]
6. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding design for multi-drug combinations.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
[TBL] [Abstract][Full Text] [Related]
8. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
9. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
10. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
11. A web application for evaluating Phase I methods using a non-parametric optimal benchmark.
Wages NA; Varhegyi N
Clin Trials; 2017 Oct; 14(5):553-557. PubMed ID: 28649874
[TBL] [Abstract][Full Text] [Related]
12. Isotonic designs for phase I trials in partially ordered groups.
Conaway M
Clin Trials; 2017 Oct; 14(5):491-498. PubMed ID: 28776422
[TBL] [Abstract][Full Text] [Related]
13. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
14. A two-dimensional biased coin design for dual-agent dose-finding trials.
Sun Z; Braun TM
Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
[TBL] [Abstract][Full Text] [Related]
15. Incorporating historical information to improve phase I clinical trials.
Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
[TBL] [Abstract][Full Text] [Related]
16. Performance of two-stage continual reassessment method relative to an optimal benchmark.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
[TBL] [Abstract][Full Text] [Related]
17. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
Lin R; Yuan Y
Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
[TBL] [Abstract][Full Text] [Related]
18. Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial.
Wages NA; Reed DR; Keng MK; Conaway MR; Petroni GR
Clin Trials; 2021 Jun; 18(3):314-323. PubMed ID: 33426919
[TBL] [Abstract][Full Text] [Related]
19. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
20. dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials.
Toumazi A; Comets E; Alberti C; Friede T; Lentz F; Stallard N; Zohar S; Ursino M
Comput Methods Programs Biomed; 2018 Apr; 157():163-177. PubMed ID: 29477425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]